人类免疫缺陷病毒1／2型抗体检测酶联免疫试剂盒的研制

采用二聚体合成肽（ＨＩＶ－１ｇｐ４１、ｇｐ１２０、ｐ２４和ＨＩＶ－２ｇｐ３６）包被酶标板条制备成固相抗原,与鼠抗人ＩｇＧ单克隆抗体酶标记物、底物ＴＭＢ及阴阳性参考血清配套制备成ＨＩＶ抗体ＥＩＡ试剂盒,专供检测人血清或血浆ＨＩＶ１／２抗体之用。以荷兰、韩国及万泰试剂作为对照,用该试剂盒对检定所的Ｐａｎｅｌ标准及献血员１５５５０例（其中ＨＣＶ抗体阳性１２８例,ＨＢｓＡｇ阳性４６例）进行检测,四种试剂对检定所Ｐａｎｅｌ标准的１３份阳性血清均呈阳性反应,２８份阴性血清均为阴性;献血员１５５５０例,四种试剂对其中１份血清均呈阳性反应,经Ｗｅｓｔｅｒｎｂｌｏｔ试验证实为阴性,四种试剂的阴性检出率均为９９．９９％。连续制备三批试剂经中国药品生物制品检定所检定,所检项目全部合格;同时委托检定所进行临床考核,４７份阳性血清全部呈阳性反应,１５０份阴性血清全部为阴性。说明该试剂盒具有很好的敏感性和特异性。     

我国首次发现的HIV—1和HIV—2双重感染样品中病毒部分基因的序列特 …

上海市卫生检疫局送检了一例ＨＩＶ－１和ＨＩＶ－２抗体检测均呈阳性的双重感染样品,对其感染的ＨＩＶ前病毒的ｇａｇ和ｅｎｖ基因区进行了序列分析,首次阐明我国发现的ＨＩＶ双重感染样品的ＨＩＶ部分基因特征。从ＨＩＶ感染者淋巴细胞（ｐｅｒｉｐｈｅｒａｌ ｂｌｏｏｄ ｍｏｎｏｎｕｃｌｅａｒ ｃｅｌｌｓ,ＰＢＭＣ）中提取前病毒ＤＮＡ,分别使用ＨＩＶ－１和ＨＩＶ－２特异性引特用套式ＰＣＲ扩增ＨＩＶ－１和ＨＩＶ－２     

人工合成多肽检测抗HIV－1和HIV－2抗体的研究

采用固相法合成ＨＩＶ－１和ＨＩＶ－２两个多肽,建立了用混合多肽为包被抗原检测ＨＩＶ－１和ＨＩＶ－２感染的间接酶联免疫吸附法。检测４６份抗ＨＩＶ－１和ＨＩＶ－２抗体阳性血清标本以及９４份对照血清标本,与ＵＢＩ试剂比较,其阳性符合率为９７．８％,阴性符合率为１００％,总符合率为９９．３％。实验结果表明,此法可用于ＨＩＶ－１和ＨＩＶ－２感染的检测。     

人类免疫缺陷病毒1型感染中的抗体中和反应

本文介绍了人类免疫缺陷病毒１型（ＨＩＶ－１）感染中有关中和抗体研究的新近进展,包括中和抗体反应的特异性,如中和表位的种类和表达,ＨＩＶ中和反应的机制等。地ＨＩＶ－１ｇｐ１２０和ｇｐ４１分子的研究结果资料,作了较为详尽的描述。文中尚提出了ＨＩＶ感染预防疫苗研制的途径。     

人源单克隆抗人免疫缺陷病毒1型抗体Fab段基因的获得

应用噬苏体抗体库技术有效地筛选出了多株抗ＨＩＶ－１人源单克隆抗体。以逆转录聚合酶链反应（ＲＴ－ＰＣＲ）从ＨＩＶ－１感染者外周血淋巴细胞中扩增抗体轻重链可变区基因,插入载体ｐＣＯＭＢ３,建立噬菌体抗体库。分别以ＨＩＶ－１ｇｐ１２０和ｇｐ１６０为固相抗原,经过多轮筛选,从中获得了多株抗ＨＩＶ－１ｇｐ４１、ｇｐ１２０和ｇｐ１６０的单克隆抗体Ｆａｂ段基因。抗ＨＩＶ特异性噬菌体抗体随抗体库的筛选高度富集,抗     

HIV—1抗体阳性血浆中HIV—1病毒基因分型研究

为了解ＨＩＶ抗体阳性血浆中的ＨＩＶ１病毒基因亚型的情况,应用逆转录ＰＣＲ和ＤＮＡ序列测定技术,对６份获自高危人群的抗ＨＩＶ１阳性血浆进行序列分析和基因亚型分型的研究,结果表明均属ＨＩＶ１Ｂ亚型。Ｖ３环氨基酸序列分析指出这些ＨＩＶ１Ｂ亚型病毒株与泰国ＨＩＶ１Ｂ亚型病毒株核苷酸和氨基酸序列相似;同时发现ＨＩＶ１ｃＤＮＡ和氨基酸序列均相同,推测这６份标本可能来自同时感染同一株ＨＩＶ病毒的感染者。本研究对了解高危人群中ＨＩＶ１流行的遗传变异和ＨＩＶ１亚型病毒株的分子流行病分析具有一定的意义。     

HIV—1 SF2株env基因（120）在大肠杆菌中的表达

运用基因重组技术,将ＨＩＶ－１ ＳＦ２株编码外膜蛋白ｇｐ１２０的ｅｎｖ基因片段与原核载体ｐＢＶ２２０进行重组,构建成质粒ｐＢＶＳＦ２ｅｎｖ,并在大肠杆菌（Ｅ．ＣｏｉｌＤＨ１０ｂ）中获得表达,经Ｗｅｓｔｅｍｂｌｏｔ反应证实,该重组蛋白与来自ＨＩＶ－１感染者的血清（含多克隆抗体）发生特异性反应。     

巨噬细胞,细胞因子与人类免疫缺陷病毒感染的关系

目的研究认为在人类免疫缺陷病毒（ＨＩＶ）感染过程中除了ＣＤ４＾＋Ｔ细胞外,单核巨噬细胞是ＨＩＶ最易侵犯的目标。同时认为ＨＩＶ感染单核－巨噬细胞不仅受各种细胞因子的调节,而且ＨＩＶ的感染能影响因素的产生。本文重点介绍限ＨＩＶ感染单核－巨噬细胞的机制、体内外有关细胞因子产生的研究及各种细胞因子对ＨＩＶ表达的调节作用。通过细胞因子网络功能的研究,进一步阐明ＨＩＶ致病机制,并积极探索出治疗ＨＩＶ感染造成免     

HIV—1gp41基因的高效表达及表达产物的纯化

为了获得高效表达的人类免疫缺陷病毒（ＨＩＶ１）ｇｐ４１蛋白,从而为ＨＩＶ１基因工程诊断抗原的国产化打下基础,用ＰＣＲ的方法从ＨＩＶ１全基因序列中扩增出编码ｇｐ４１Ｎ端的６９０ｂｐ片段。经酶切后,克隆到ｐＥＴ２８ａ载体中,再将重组质粒转化到表达宿主菌ＢＬ２１（ＤＥ３）中,经ＩＰＴＧ诱导,高效表达出ｇｐ４１蛋白。间接ＥＬＩＳＡ、Ｗｅｓｔｅｒｎｂｌｏｔ、ＳＤＳＰＡＧＥ电泳证实,该表达产物具有良好的抗原性和特异性,且表达量约占总菌体蛋白的４５％。重组蛋白经金属鏊合纯化,纯度达９９％。     

1992—1994年HIV—1国际流行株和云南株膜蛋白V3区氨基酸共有序列比较

对１９９２～１９９４年间１６个云南ＨＩＶ１株膜蛋白基因Ｖ３区进行了ＤＮＡ序列测定,经计算机ＤＮＡＳＩＳ及ＰＲＯＳＩＳ软件进行同源性分析,得出其相应的氨基酸共有序列ＹＮＶ３和两组共有序列ＹＮＶ３Ａ和ＹＮＶ３Ｂ,计算了ＹＮＶ３中每个氨基酸的保守性。分别将ＹＮＶ３Ａ和ＹＮＶ３Ｂ与世界各地的ＨＩＶ１代表株的相应序列进行了同源性比较。结果表明,ＨＩＶ１云南株膜蛋白Ｖ３区氨基酸共有序列ＹＮＶ３中每个氨基酸的平均变异度为７．６６％。两组共有序列ＹＮＶ３Ａ和ＹＮＶ３Ｂ,分别与ＨＩＶ１美欧株及泰国流行株Ｂ亚群相应序列有较高同源性。这一结果提示,在进化上云南瑞丽ＨＩＶ１流行毒株间有非常密切的关系,在这一时期该地区的流行毒株以ＨＩＶ１美欧株、泰国株Ｂ亚群及其衍生株为主。     

HIV-1 p24和SIV p27两种ELISA试剂盒检测SIV p27抗原的比较

目的由于检测SIV p27抗原试剂盒来源困难,有时不稳定,鉴于HIV-1 p24与SIVp27有较强的交叉抗原,本研究比较HIV-1 p24和SIV p27两种ELISA试剂盒检测SIV p27抗原得出的结果是否存在一定的相关性。方法 HIV-1 p24和SIV p27两种ELISA试剂盒定性和定量检测样品中SIV p27抗原,并对检测结果进行回归和相关分析。结果 HIV-1 p24和SIV p27两种ELISA试剂盒检测SIV p27抗原的灵敏度分别是150 pg/mL和62.5 pg/mL。两种试剂盒检测病毒液和血浆中SIV p27抗原的定性结果一致。定量结果的统计分析得出病毒液的直线回归决定系数R2=0.857,直线相关系数r=0.926,P〈0.01,直线正相关程度较高;血浆的直线回归决定系数R2=0.512,直线相关系数r=0.716,P〈0.05,直线正相关程度较低。结论 HIV-1 p24 ELISA试剂盒能够替代SIVp27 ELISA试剂盒定性检测病毒液和血浆中SIV p27抗原,但只能定量检测病毒液中SIV p27抗原。     

Specificity of interaction of INI1/hSNF5 with retroviral integrases and its functional significance

Integrase interactor 1 (INI1)/hSNF5 is a host factor that directly interacts with human immunodeficiency virus type 1 (HIV-1) integrase and is incorporated into HIV-1 virions. Here, we show that while INI1/hSNF5 is completely absent from purified microvesicular fractions, it is specifically incorporated into HIV-1 virions with an integrase-to-INI1/hSNF5 stoichiometry of approximately 2:1 (molar ratio). In addition, we show that INI1/hSNF5 is not incorporated into related primate lentiviral and murine retroviral particles despite the abundance of the protein in producer cells. We have found that the specificity in incorporation of INI1/hSNF5 into HIV-1 virions is directly correlated with its ability to exclusively interact with HIV-1 integrase but not with other retroviral integrases. This specificity is also reflected in our finding that the transdominant mutant S6, harboring the minimal integrase interaction domain of INI1/hSNF5, blocks HIV-1 particle production but not that of the other retroviruses in 293T cells. Taken together, these results suggest that INI1/hNSF5 is a host factor restricted for HIV-1 and that S6 acts as a highly specific and potent inhibitor of HIV-1 replication.     

HIV antibody assay that gave false negative results: multicentre collaborative study.

OBJECTIVE: To identify false negative results arising from the use of a commercial kit to detect antibody to HIV-1 and HIV-2 between July 1995 and March 1996. DESIGN: The 56 laboratories in the United Kingdom that were using the assay were asked to retrieve and retest specimens with an alternative assay for HIV-1 and HIV-2. Details of false negative results were obtained and these serum samples further investigated. SUBJECTS: 24,181 patients tested with the assay who were reported as being negative for HIV antibody. An additional 497 patients were confirmed as HIV positive with the assay. RESULTS: Serum samples of 20,973 of the patients were retested, and four patients were found to have had false negative results with the kit; three further patients were found to have had false negative results in the course of other laboratory testing. The seven patients with false negative results with the kit were of diverse risk group and HIV-1 subtype. Four had evidence of recent HIV infection. CONCLUSION: The commercial kit had a sensitivity of 99.2% (497/501), or less if the additional three patients with false negative results were taken into account.     

Rapid in vitro detection of HIV-1-specific antibody secretion by cells-culture with virus antigens.

The present report describes an alternative method for in vitro detection of HIV-1-specific antibody secretion in 24h of culture employing as stimulant of peripheral blood mononuclear cells the disrupted inactivated whole virus adsorbed onto microwells in a commercial ELISA kit plates. The results obtained from this technique have showed high sensitivity and specificity since it was capable of detecting HIV-1 infection early after birth. There were neither false-positivity nor false-negativity when blood samples obtained from HIV-1 seronegative asymptomatic individuals, and HIV-1 seropositive adult patients were analyzed. This rapid, low cost, simple, highly sensitive and specific assay can be extremely useful for early diagnosis of pediatric HIV infection.     

A serological screening assay of human immunodeficiency virus type 1 antibodies based on recombinant protein p24-gp41 as a fusion protein expressed in Escherichia coli

The objective of this study was expression of a recombinant fusion protein p24-gp41 to gain a proper folding pattern of the proteins which could be recognized by specific antibodies against human immunodeficiency virus type 1 (HIV-1) for development of a reliable serodiagnostic kit. Serodiagnostic method using enzyme-linked immunosorbent assay (ELISA) with the expressed recombinant fusion protein p24-gp41 was carried out to test the sensitivity and specificity of the protein using human sera and various reference panels from Boston Biomedica Inc. (BBI). The level of the expression was determined to be 30% and the final recovery from fermentation and purification process was calculated as 80 mg/L with more than 98% purity. The developed ELISA assay was demonstrated to have 100 and 99.5% sensitivity and specificity, respectively, detecting anti-HIV-1 antibody using 900 positive and 10,000 negative human sera. The developed assay showed reliable results in comparison with other reference HIV ELISA kits using various BBI panels as well. In conclusion, the recombinant fusion protein p24-gp41 was expressed and used to develop a serodiagnostic kit for screening of the HIV-1 with high sensitivity (100%) and specificity (99.5%) which could be useful for screening large groups of blood donors.     

Comparative analysis of Rev function in human immunodeficiency virus types 1 and 2.

The Rev proteins of the related but distinct human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2) display incomplete functional reciprocity. One possible explanation for this observation is that HIV-2 Rev is unable to interact with the HIV-1 Rev-response element (RRE1). However, an analysis of the biological activity of chimeric proteins derived from HIV-1 and HIV-2 Rev reveals that this target specificity does not map to the Rev RNA binding domain but is instead primarily determined by sequences known to mediate Rev multimerization. Both HIV-1 and HIV-2 Rev are shown to bind the RRE1 in vitro with identical RNA sequence specificity. The observation that HIV-2 Rev can inhibit RRE1-dependent HIV-1 Rev function in trans indicates that the direct interaction of HIV-2 Rev with the RRE1 also occurs in vivo. These data suggest that HIV-2 Rev forms a protein-RNA complex with the RRE1 that leads to only minimal Rev activity. It is hypothesized that this low level of Rev function results from the incomplete and/or aberrant multimerization of HIV-2 Rev on this heterologous RNA target sequence.     

A robust HIV-1 viral load detection assay optimized for Indian sub type C specific strains and resource limiting setting

Background

Human Immunodeficiency Virus Type 1 (HIV-1) viral load testing at regular intervals is an integral component of disease management in Acquired Immunodeficiency Syndrome (AIDS) patients. The need in countries like India is therefore an assay that is not only economical but efficient and highly specific for HIV-1 sub type C virus. This study reports a SYBR Green-based HIV-1 real time PCR assay for viral load testing and is designed for enhanced specificity towards HIV-1 sub type C viruses prevalent in India.

Results

Linear regression of the observed and reference concentration of standards used in this study generated a correlation coefficient of 0.998 (p < 0.001). Lower limit of detection of the test protocol was 50 copies/ml of plasma. The assay demonstrated 100% specificity when tested with negative control sera. The Spearman coefficient of the reported assay with an US-FDA approved, Taqman probe-based commercial kit was found to be 0.997. No significant difference in viral load was detected when the SYBR Green based assay was used to test infected plasma stored at -20°C and room temperature for 7 days respectively (Wilcoxon signed rank test, p = 0.105). In a comparative study on 90 pretested HIV-1 positive samples with viral loads ranging from 5,000–25,000 HIV-1 RNA copies/ml and between two commercial assays it was found that the later failed to amplify in 13.33% and 10% samples respectively while in 7.77% and 4.44% samples the copy number values were reduced by >0.5 log value, a figure that is considered clinically significant by physicians.

Conclusion

The HIV-1 viral load assay reported in this study was found to be robust, reliable, economical and effective in resource limited settings such as those existing in India. PCR probes specially designed from HIV-1 Subtype C-specific nucleotide sequences originating from India imparted specificity towards such isolates and demonstrated superior results when compared to two similar commercial assays widely used in India.     

Dot-ELISA法检测血液及唾液HIV抗体的应用评价

评价人类免疫缺陷病毒1+2型抗体检测试剂盒(Dot-ELISA法)检测血清和唾液样本的临床性能。采用对照试验研究,选取背景清晰的研究对象200例,采集同一研究对象的血清和唾液样本,应用万泰生物药业公司生产的人类免疫缺陷病毒1+2型抗体检测试剂盒作为考核试剂,法国生物梅里埃公司生产的人类免疫缺陷病毒抗体诊断试剂盒(ELISA法)作为参考试剂,考核试剂检测结果与参考试剂及研究对象背景进行比较分析。考核试剂检测血清HIV抗体与参考试剂相比较,阳性符合率100%,阴性符合率100%,总符合率100%,Kappa值1.00,一致性为最强;考核试剂检测唾液HIV抗体与参考试剂检测结果相比较,阳性符合率98.78%,阴性符合率100%,总符合率99.50%,Kappa值0.99,一致性为最强。Dot-ELISA法人类免疫缺陷病毒1+2型抗体检测试剂盒对血清及唾液样本检测性能优越,适合HIV抗体快速筛查。